Anti-human TNFα (Infliximab Biosimilar) Research Grade
Amount: 100ug
Product Details
This non-therapeutic biosimilar antibody incorporates the same variable regions as the therapeutic antibody Infliximab, making it ideal for research use. It specifically binds to human tumor necrosis factor-alpha (TNFα), a multifunctional proinflammatory cytokine that plays a central role in immune regulation and inflammation. TNFα exists as a soluble 17 kDa monomer that forms active homotrimers in circulation, as well as a 26 kDa membrane-bound form. A member of the TNF superfamily, TNFα signals through two receptors—TNFR1 (p55) and TNFR2 (p75)—both of which can be activated by the soluble and membrane-bound forms of the cytokine. TNFα is primarily produced by activated macrophages in response to foreign antigens such as bacterial lipopolysaccharides, viruses, parasites, mitogens, and other cytokines. It is also expressed by monocytes, neutrophils, NK cells, CD4+ T cells, and specialized dendritic cells. TNFα regulates numerous biological processes, including immune responses, cell proliferation, differentiation, apoptosis, antitumor activity, inflammation, cachexia, septic shock, hematopoiesis, and viral replication. Dysregulated TNFα signaling has been implicated in various conditions such as autoimmune diseases, insulin resistance, and cancer. Infliximab neutralizes TNFα by blocking its interaction with TNFR1 and TNFR2, thereby suppressing the inflammatory response associated with autoimmune and chronic inflammatory diseases.
Specifications
Product name: Anti-human TNFα (Infliximab Biosimilar) Research Grade
Species: Human
Storage condition: 4°C for short term; -20°C for long term
Note: For research use only. Not suitable for human use
Isotype: IgG1
Clonality: Monoclonal Antibody
Purity: >95% Determined by SDS-PAGE
Sterility: 0.2 µm filtration
Purification: Protein A
RRID: AB_2894727
Molecular Weight: 150 kDa
Amount: 100ug
Product Details
This non-therapeutic biosimilar antibody incorporates the same variable regions as the therapeutic antibody Infliximab, making it ideal for research use. It specifically binds to human tumor necrosis factor-alpha (TNFα), a multifunctional proinflammatory cytokine that plays a central role in immune regulation and inflammation. TNFα exists as a soluble 17 kDa monomer that forms active homotrimers in circulation, as well as a 26 kDa membrane-bound form. A member of the TNF superfamily, TNFα signals through two receptors—TNFR1 (p55) and TNFR2 (p75)—both of which can be activated by the soluble and membrane-bound forms of the cytokine. TNFα is primarily produced by activated macrophages in response to foreign antigens such as bacterial lipopolysaccharides, viruses, parasites, mitogens, and other cytokines. It is also expressed by monocytes, neutrophils, NK cells, CD4+ T cells, and specialized dendritic cells. TNFα regulates numerous biological processes, including immune responses, cell proliferation, differentiation, apoptosis, antitumor activity, inflammation, cachexia, septic shock, hematopoiesis, and viral replication. Dysregulated TNFα signaling has been implicated in various conditions such as autoimmune diseases, insulin resistance, and cancer. Infliximab neutralizes TNFα by blocking its interaction with TNFR1 and TNFR2, thereby suppressing the inflammatory response associated with autoimmune and chronic inflammatory diseases.
Specifications
Product name: Anti-human TNFα (Infliximab Biosimilar) Research Grade
Species: Human
Storage condition: 4°C for short term; -20°C for long term
Note: For research use only. Not suitable for human use
Isotype: IgG1
Clonality: Monoclonal Antibody
Purity: >95% Determined by SDS-PAGE
Sterility: 0.2 µm filtration
Purification: Protein A
RRID: AB_2894727
Molecular Weight: 150 kDa
Amount: 100ug
Product Details
This non-therapeutic biosimilar antibody incorporates the same variable regions as the therapeutic antibody Infliximab, making it ideal for research use. It specifically binds to human tumor necrosis factor-alpha (TNFα), a multifunctional proinflammatory cytokine that plays a central role in immune regulation and inflammation. TNFα exists as a soluble 17 kDa monomer that forms active homotrimers in circulation, as well as a 26 kDa membrane-bound form. A member of the TNF superfamily, TNFα signals through two receptors—TNFR1 (p55) and TNFR2 (p75)—both of which can be activated by the soluble and membrane-bound forms of the cytokine. TNFα is primarily produced by activated macrophages in response to foreign antigens such as bacterial lipopolysaccharides, viruses, parasites, mitogens, and other cytokines. It is also expressed by monocytes, neutrophils, NK cells, CD4+ T cells, and specialized dendritic cells. TNFα regulates numerous biological processes, including immune responses, cell proliferation, differentiation, apoptosis, antitumor activity, inflammation, cachexia, septic shock, hematopoiesis, and viral replication. Dysregulated TNFα signaling has been implicated in various conditions such as autoimmune diseases, insulin resistance, and cancer. Infliximab neutralizes TNFα by blocking its interaction with TNFR1 and TNFR2, thereby suppressing the inflammatory response associated with autoimmune and chronic inflammatory diseases.
Specifications
Product name: Anti-human TNFα (Infliximab Biosimilar) Research Grade
Species: Human
Storage condition: 4°C for short term; -20°C for long term
Note: For research use only. Not suitable for human use
Isotype: IgG1
Clonality: Monoclonal Antibody
Purity: >95% Determined by SDS-PAGE
Sterility: 0.2 µm filtration
Purification: Protein A
RRID: AB_2894727
Molecular Weight: 150 kDa